Co-Diagnostics Inc logo

CODX

Co-Diagnostics Inc

$3.8

Earnings Summary

Revenue
$22.7Mn
Net Profits
$11.71Mn
Net Profit Margins
51.61%
PE Ratio
4.72

Highlights

Revenue:

Co-Diagnostics Inc’s revenue jumped 13.35% since last year same period to $22.7Mn in the Q1 2022. On a quarterly growth basis, Co-Diagnostics Inc has generated 11.26% jump in its revenue since last 3-months.

Net Profits:

Co-Diagnostics Inc’s net profit jumped 48.31% since last year same period to $11.71Mn in the Q1 2022. On a quarterly growth basis, Co-Diagnostics Inc has generated 56.23% jump in its net profits since last 3-months.

Net Profit Margins:

Co-Diagnostics Inc’s net profit margin jumped 30.83% since last year same period to 51.61% in the Q1 2022. On a quarterly growth basis, Co-Diagnostics Inc has generated 40.41% jump in its net profit margins since last 3-months.

PE Ratio:

Co-Diagnostics Inc’s price-to-earnings ratio after this Q1 2022 earnings stands at 4.72.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Co-Diagnostics Inc post its latest quarter earnings

EPS Estimate Current Quarter
0.1
EPS Estimate Current Year
0.1

Highlights

EPS Estimate Current Quarter:

Co-Diagnostics Inc’s earning per share (EPS) estimates for the current quarter stand at 0.1 - a -41.18% fall from last quarter’s estimates.

EPS Estimate Current Year:

Co-Diagnostics Inc’s earning per share (EPS) estimates for the current year stand at 0.1.

Key Ratios

Key ratios of the Co-Diagnostics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
0.34
Return on Assets (ROA)
0.15
Return on Equity (ROE)
0.24
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Co-Diagnostics Inc’s earning per share (EPS) jumped 30.77% since last year same period to 0.34 in the Q1 2022. This indicates that the Co-Diagnostics Inc has generated 30.77% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Co-Diagnostics Inc’s return on assets (ROA) stands at 0.15.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Co-Diagnostics Inc’s return on equity (ROE) stands at 0.24.

Dividend Per Share (DPS):

Co-Diagnostics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
0.17
0.34
100%

Company Information

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Organisation
Co-Diagnostics Inc
Headquarters
Salt Lake City, Utah, US
Employees
37
Industry
Health Technology
CEO
Dwight Egan